Page 8 - Pharmaceuticals

Baxter acquires Claris Injectables for $625 million

With this acquisition, the US-based pharma company will add global portfolio of sterile injectables, robust pipeline, and manufacturing capabilities

Global drug market to reach $1.5 trillion in 2021: Study

Most global spending growth will be fuelled by significant innovations in oncology, autoimmune and diabetes treatments, according to QuintilesIMS Institute research

Dr Reddy's launches antifungal skin cream in US

The product is the generic equivalent of Taro Pharmacueticals' nystatin and triamcinolone acetonide cream

Zydus plans to launch ulcer drug mesalamine in US by March 2020

This follows a settlement of the patent litigation related to Allergan's Delzicol (mesalamine)

Natco receives US FDA approval for generic budesonide capsule

Budesonide capsule (enteric coated) is a gastroenterology medicine used for treating patients with mild to moderate Crohn's disease

Strides Shasun buys Moberg Pharma's PediaCare brand for $ 5 mn

With this acquisition, the company has strengthen its consumer healthcare portfolio

Aurobindo Pharma buys Teva's calcium & vitamin D3 products in France

The company's French subsidiary, Arrow Generiques, will acquire the right & title in calcium and calcium-vitamin D3 products, including the use of Orocal trademark

Cipla divests stake in US-based Chase Pharmaceuticals to Allergan

This follows an agreement by Allergan to acquire Chase by paying $125 million upfront plus potential regulatory and commercial milestones of up to $875 million

Suven Life bags product patents in China and Mexico

Patent was granted for the new chemical entities (NCEs) used in the treatment of disorders associated with neurodegenerative diseases

FICCI launches self-regulation code of conduct for e-pharmacy

This code is an attempt by the industry to adhere to the highest professional standards and to have proper safeguards so as to ensure that consumer's health and safety is not compromised

Zydus Cadila CMD Pankaj Patel to be next FICCI president

He will take over from Harshavardhan Neotia, chairman of Ambuja Neotia Group

Smart sourcing of comparators to reduce biosimilars development cost

Sourcing comparators, the reference drugs used during clinical trials of biosimilars, from emerging markets can cost 50% less than developed countries, says Dr Piyush Gupta

Lupin launches Activella generic in US

Activella (estradiol and norethindrone acetate tablets), marketed by Amneal Pharmaceuticals, had annual sales of $ 91.1 million in the US, according to IMS Health

Lupin launches injectable iron formulation in India

The company has acquired exclusive marketing rights for this product from Danish firm Pharmacosmos

Advanced Enzymes buys 70% stake in APIs maker JC Biotech

The acquisition will strengthen Advanced Enzymes' leadership position in API serratiopeptidase with 80% market share and also enables its foray into biopharma & algal DHA

Dr Reddy's partners Gland Pharma in the US to market injectables

Through this alliance two companies are aiming to target a range of injectable products - the combined annual sale of which (branded as well as generics) is estimated at about $ 1 billion

Indian Patent Office to create awareness programme for new IPR policy

The aim of the new policy is to provide IP protection in India to the innovator in a reasonable period of time without much problems, says O P Gupta, Controller General of Patents

The $ 240 bn biosimilar opportunity: Buddy up to succeed

Indian pharma companies will have to adopt strategy of collaboration (with global or domestic firms) to succeed in the market as cost of developing biosimilars are very high, says Pushpa Vijayraghavan

Sun Pharma & ICGEB to jointly develop dengue vaccine

The pharma company will fund & support further development of a vaccine candidate developed by International Centre for Genetic Engineering and Biotechnology (ICGEB)

Prevalence of infectious diseases to propel antibiotics market to reach $ 57 bn

Currently, the required antibiotic treatment is available only to one third of the infected population, thereby increasing the disease burden, says a Grand View Research report